A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

<h4>Background</h4> <p>GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood–brain barrier (BBB) penetration. In this expansion cohort within a...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Brown, N, Williams, M, Arkenau, H, Fleming, R, Tolson, J, Yan, L, Zhang, J, Swartz, L, Singh, R, Auger, K, Lenox, L, Cox, D, Lewis, Y, Plisson, C, Searle, G, Saleem, A, Blagden, S, Mulholland, P
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	Oxford University Press 2018
Những chủ đề:	focal adhesions kinetics neoplasms pharmacokinetics cerebral edema fatigue positron-emission tomography brain toxic effect phosphotransferases glioblastoma safety kinase inhibitors

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

Những quyển sách tương tự